Roche’s Gazyva/Gazyvaro showed superior progression-free survival
Roche announced positive results from the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma. Results from a pre-planned interim analysis showed that Gazyva/Gazyvaro-based treatment significantly reduced the risk of disease worsening or death. May 27, 2016